|
UA59384C2
(uk)
*
|
1996-12-20 |
2003-09-15 |
Пфайзер, Інк. |
Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
|
|
TR199902012T2
(xx)
*
|
1997-02-21 |
2000-01-21 |
Bayer Aktiengesellschaft |
Arils�lfonamidler ve analoglar�
|
|
CA2318731C
(en)
*
|
1998-01-29 |
2012-05-29 |
Tularik Inc. |
Ppar-gamma modulators
|
|
DE19837627A1
(de)
|
1998-08-19 |
2000-02-24 |
Bayer Ag |
Neue Aminosäureester von Arylsulfonamiden und Analoga
|
|
US7041691B1
(en)
|
1999-06-30 |
2006-05-09 |
Amgen Inc. |
Compounds for the modulation of PPARγ activity
|
|
DE10015866A1
(de)
|
2000-03-30 |
2001-10-11 |
Bayer Ag |
Aryl- und Heteroarylsulfonate
|
|
US20090124690A1
(en)
*
|
2000-04-03 |
2009-05-14 |
Alberte Randall S |
Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins
|
|
WO2001082916A2
(en)
*
|
2000-05-03 |
2001-11-08 |
Tularik Inc. |
Combination therapeutic compositions and methods of use
|
|
US20030171399A1
(en)
*
|
2000-06-28 |
2003-09-11 |
Tularik Inc. |
Quinolinyl and benzothiazolyl modulators
|
|
DE10047486A1
(de)
*
|
2000-09-26 |
2002-04-11 |
Bayer Ag |
Phenoxyphenyl Alkansulfonate
|
|
US20020091114A1
(en)
|
2000-10-04 |
2002-07-11 |
Odile Piot-Grosjean |
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
|
|
UA75093C2
(en)
|
2000-10-06 |
2006-03-15 |
Dimensional Pharm Inc |
Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors
|
|
AU2006200813A1
(en)
*
|
2000-11-24 |
2006-03-16 |
Novartis Ag |
Naphthalene derivatives
|
|
GB0028702D0
(en)
*
|
2000-11-24 |
2001-01-10 |
Novartis Ag |
Organic compounds
|
|
US6708906B2
(en)
*
|
2000-12-29 |
2004-03-23 |
Siemens Automotive Corporation |
Modular fuel injector having a surface treatment on an impact surface of an electromagnetic actuator and having an integral filter and dynamic adjustment assembly
|
|
US7507767B2
(en)
|
2001-02-08 |
2009-03-24 |
Schering Corporation |
Cannabinoid receptor ligands
|
|
WO2003007887A2
(en)
|
2001-07-20 |
2003-01-30 |
Merck & Co., Inc. |
Substituted imidazoles as cannabinoid receptor modulators
|
|
US20040171613A1
(en)
*
|
2001-12-27 |
2004-09-02 |
Japan Tobacco Inc. |
Therapeutic agent for non-immediate type allergic diseases
|
|
WO2003061699A1
(en)
*
|
2001-12-27 |
2003-07-31 |
Japan Tobacco, Inc. |
Remedies for allergic diseases
|
|
PT1477186E
(pt)
*
|
2002-02-19 |
2010-02-11 |
Shionogi & Co |
Antipruriginosos
|
|
AU2003217961B2
(en)
|
2002-03-08 |
2008-02-28 |
Signal Pharmaceuticals, Llc |
Combination therapy for treating, preventing or managing proliferative disorders and cancers
|
|
NZ534757A
(en)
|
2002-03-12 |
2006-07-28 |
Merck & Co Inc |
Substituted amides
|
|
EP1490043A4
(en)
|
2002-03-26 |
2007-05-30 |
Merck & Co Inc |
SPIROCYCLIC AMIDS AS CANNABINOID RECEPTOR MODULATORS
|
|
WO2003082191A2
(en)
|
2002-03-28 |
2003-10-09 |
Merck & Co., Inc. |
Substituted 2,3-diphenyl pyridines
|
|
DE10215942A1
(de)
*
|
2002-04-11 |
2003-10-23 |
Bayer Ag |
Wässrige Formulierungen von (2-Hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorbutan-1-sulfonat
|
|
EP1499306A4
(en)
|
2002-04-12 |
2007-03-28 |
Merck & Co Inc |
BICYCLIC AMIDE
|
|
US6908935B2
(en)
|
2002-05-23 |
2005-06-21 |
Amgen Inc. |
Calcium receptor modulating agents
|
|
US7176322B2
(en)
|
2002-05-23 |
2007-02-13 |
Amgen Inc. |
Calcium receptor modulating agents
|
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
|
US7094789B2
(en)
*
|
2002-07-22 |
2006-08-22 |
Asahi Kasei Pharma Corporation |
5-substituted isoquinoline derivatives
|
|
CA2494824A1
(en)
*
|
2002-08-08 |
2004-02-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
|
|
JP2006510597A
(ja)
|
2002-09-27 |
2006-03-30 |
メルク エンド カムパニー インコーポレーテッド |
置換ピリミジン類
|
|
TW200510311A
(en)
*
|
2002-12-23 |
2005-03-16 |
Millennium Pharm Inc |
CCr8 inhibitors
|
|
US7491827B2
(en)
*
|
2002-12-23 |
2009-02-17 |
Millennium Pharmaceuticals, Inc. |
Aryl sulfonamides useful as inhibitors of chemokine receptor activity
|
|
EP1590327A1
(en)
*
|
2002-12-23 |
2005-11-02 |
Millennium Pharmaceuticals, Inc. |
Ccr8 inhibitors
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
WO2005037286A1
(en)
*
|
2003-03-25 |
2005-04-28 |
Vasopharm Biotech Gmbh |
Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
|
|
UA84020C2
(ru)
*
|
2003-09-11 |
2008-09-10 |
Тиботек Фармасьютикелз Лтд. |
Ингибитор проникновения вируса вил
|
|
CA2538291A1
(en)
*
|
2003-09-18 |
2005-03-31 |
Merck & Co., Inc. |
Substituted sulfonamides
|
|
AU2004274309B2
(en)
|
2003-09-22 |
2010-04-08 |
Msd K.K. |
Novel piperidine derivative
|
|
US7223761B2
(en)
*
|
2003-10-03 |
2007-05-29 |
Amgen Inc. |
Salts and polymorphs of a potent antidiabetic compound
|
|
TW200522944A
(en)
|
2003-12-23 |
2005-07-16 |
Lilly Co Eli |
CB1 modulator compounds
|
|
US20050250820A1
(en)
*
|
2004-03-08 |
2005-11-10 |
Amgen Inc. |
Therapeutic modulation of PPARgamma activity
|
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
|
US7820654B2
(en)
*
|
2004-09-23 |
2010-10-26 |
Dr. Reddy's Laboratories Ltd. |
Pyrimidine compounds, process for their preparation and compositions containing them
|
|
EP2286840A3
(en)
|
2004-11-01 |
2013-09-04 |
Amylin Pharmaceuticals, LLC |
Treatment of obesity and related diseases
|
|
US8394765B2
(en)
*
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
|
CA2587667A1
(en)
*
|
2004-11-15 |
2006-05-18 |
Taisho Pharmaceutical Co., Ltd. |
Imine compound
|
|
WO2006093253A1
(ja)
*
|
2005-03-03 |
2006-09-08 |
Santen Pharmaceutical Co., Ltd. |
キノリルアルキルチオ基を有する新規環式化合物
|
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
|
CA2609388C
(en)
|
2005-05-30 |
2013-08-06 |
Banyu Pharmaceutical Co., Ltd. |
Novel piperidine derivative
|
|
US7923465B2
(en)
|
2005-06-02 |
2011-04-12 |
Glenmark Pharmaceuticals S.A. |
Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
|
CA2613678A1
(en)
|
2005-06-02 |
2006-12-07 |
Glenmark Pharmaceuticals S.A. |
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
|
JPWO2007018248A1
(ja)
|
2005-08-10 |
2009-02-19 |
萬有製薬株式会社 |
ピリドン化合物
|
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
|
EP2330124B1
(en)
|
2005-08-11 |
2015-02-25 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
|
EP1921065B1
(en)
|
2005-08-24 |
2010-10-20 |
Banyu Pharmaceutical Co., Ltd. |
Phenylpyridone derivative
|
|
WO2007029847A1
(ja)
|
2005-09-07 |
2007-03-15 |
Banyu Pharmaceutical Co., Ltd. |
二環性芳香族置換ピリドン誘導体
|
|
BRPI0616463A2
(pt)
|
2005-09-29 |
2011-06-21 |
Merck & Co Inc |
composto, composição farmacêutica, e, uso de um composto
|
|
AU2006307046A1
(en)
|
2005-10-27 |
2007-05-03 |
Msd K.K. |
Novel benzoxathiin derivative
|
|
US8158791B2
(en)
|
2005-11-10 |
2012-04-17 |
Msd K.K. |
Aza-substituted spiro derivatives
|
|
EP2081905B1
(en)
*
|
2006-07-28 |
2012-09-12 |
Boehringer Ingelheim International GmbH |
Sulfonyl compounds which modulate the cb2 receptor
|
|
JP5489333B2
(ja)
|
2006-09-22 |
2014-05-14 |
メルク・シャープ・アンド・ドーム・コーポレーション |
脂肪酸合成阻害剤を用いた治療の方法
|
|
CA2664310A1
(en)
*
|
2006-09-25 |
2008-04-03 |
Boehringer Ingelheim International Gmbh |
Compounds which modulate the cb2 receptor
|
|
AU2007301126A1
(en)
|
2006-09-28 |
2008-04-03 |
Banyu Pharmaceutical Co., Ltd. |
Diaryl ketimine derivative
|
|
WO2008098025A1
(en)
*
|
2007-02-08 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Arylsulfonamide compounds which modulate the cb2 receptor
|
|
CA2682727C
(en)
|
2007-04-02 |
2016-03-22 |
Banyu Pharmaceutical Co., Ltd. |
Indoledione derivative
|
|
EP2527360B1
(en)
|
2007-06-04 |
2015-10-28 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
JP5492092B2
(ja)
*
|
2007-11-07 |
2014-05-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｂ２受容体を調節する化合物
|
|
KR20100098628A
(ko)
*
|
2007-11-14 |
2010-09-08 |
아밀린 파마슈티칼스, 인크. |
비만 및 비만 관련 질환 및 장애의 치료 방법
|
|
US20110015181A1
(en)
|
2008-03-06 |
2011-01-20 |
Makoto Ando |
Alkylaminopyridine derivative
|
|
EP2272841A1
(en)
|
2008-03-28 |
2011-01-12 |
Banyu Pharmaceutical Co., Ltd. |
Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
|
|
EP2810951B1
(en)
|
2008-06-04 |
2017-03-15 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
AU2009261248A1
(en)
|
2008-06-19 |
2009-12-23 |
Banyu Pharmaceutical Co., Ltd. |
Spirodiamine-diarylketoxime derivative
|
|
EP2326629B1
(en)
*
|
2008-07-10 |
2013-10-02 |
Boehringer Ingelheim International GmbH |
Sulfone compounds which modulate the cb2 receptor
|
|
WO2010013595A1
(ja)
|
2008-07-30 |
2010-02-04 |
萬有製薬株式会社 |
５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
|
|
WO2010036630A2
(en)
|
2008-09-25 |
2010-04-01 |
Boehringer Ingelheim International Gmbh |
Compounds which selectively modulate the cb2 receptor
|
|
WO2010047982A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
JP5635991B2
(ja)
|
2008-10-30 |
2014-12-03 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
イソニコチンアミドオレキシン受容体アンタゴニスト
|
|
JP5557845B2
(ja)
|
2008-10-31 |
2014-07-23 |
メルク・シャープ・アンド・ドーム・コーポレーション |
糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
|
|
WO2010075069A1
(en)
|
2008-12-16 |
2010-07-01 |
Schering Corporation |
Bicyclic pyranone derivatives as nicotinic acid receptor agonists
|
|
US20110245209A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
|
EP2379076B1
(en)
|
2008-12-23 |
2014-11-12 |
The Trustees of Columbia University in the City of New York |
Phosphodiesterase inhibitors and uses thereof
|
|
US8299103B2
(en)
|
2009-06-15 |
2012-10-30 |
Boehringer Ingelheim International Gmbh |
Compounds which selectively modulate the CB2 receptor
|
|
JP5756800B2
(ja)
|
2009-06-16 |
2015-07-29 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
|
|
JP2013505295A
(ja)
*
|
2009-09-22 |
2013-02-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｂ２受容体を選択的に調節する化合物
|
|
EP2509961B1
(en)
|
2009-12-11 |
2016-03-09 |
Autifony Therapeutics Limited |
Imidazolidinedione derivatives
|
|
US9315454B2
(en)
|
2010-01-15 |
2016-04-19 |
Boehringer Ingelheim International Gmbh |
Compounds which modulate the CB2 receptor
|
|
US8895596B2
(en)
|
2010-02-25 |
2014-11-25 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
EP2542539B1
(en)
|
2010-03-05 |
2014-02-26 |
Boehringer Ingelheim International GmbH |
Tetrazole compounds which selectively modulate the cb2 receptor
|
|
JP5746764B2
(ja)
|
2010-07-22 |
2015-07-08 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｂ２受容体を調節する化合物
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
BR112013021236B1
(pt)
|
2011-02-25 |
2021-05-25 |
Merck Sharp & Dohme Corp |
composto derivado de benzimidazol, e, composição
|
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
|
US9527875B2
(en)
|
2012-08-02 |
2016-12-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
RU2015140066A
(ru)
|
2013-02-22 |
2017-03-30 |
Мерк Шарп И Доум Корп. |
Противодиабетические бициклические соединения
|
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
EP2803668A1
(en)
|
2013-05-17 |
2014-11-19 |
Boehringer Ingelheim International Gmbh |
Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
|
|
SI3004138T1
(sl)
|
2013-06-05 |
2024-07-31 |
Bausch Health Ireland Limited |
Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
DK3054936T5
(da)
|
2013-10-10 |
2024-03-18 |
Eastern Virginia Medical School |
4-((2-hydroxy-3-methoxybenzyl)amino) benzensulfonamid derivater som 12-lipoxygenase inhibitorer
|
|
KR102431436B1
(ko)
|
2014-08-29 |
2022-08-10 |
테스 파마 에스.알.엘. |
α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
|
|
US9585867B2
(en)
|
2015-08-06 |
2017-03-07 |
Charles Everett Ankner |
Cannabinod formulation for the sedation of a human or animal
|
|
AR109950A1
(es)
|
2016-10-14 |
2019-02-06 |
Tes Pharma S R L |
INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
|
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
AR117122A1
(es)
|
2018-11-20 |
2021-07-14 |
Tes Pharma S R L |
INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
|
|
US11098029B2
(en)
|
2019-02-13 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
|
WO2020167701A1
(en)
|
2019-02-13 |
2020-08-20 |
Merck Sharp & Dohme Corp. |
Pyrrolidine orexin receptor agonists
|
|
US12312332B2
(en)
|
2019-08-08 |
2025-05-27 |
Merck Sharp & Dohme Llc |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
|
BR112023002957A2
(pt)
|
2020-08-18 |
2023-04-04 |
Merck Sharp & Dohme Llc |
Composto, composição farmacêutica, e, métodos para tratar narcolepsia e para tratar hipersonia em um sujeito mamífero
|